Verition Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Verition Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$184K	Sell	13,264 -16,223	-55%	-$228K	﹤0.01%	1964
2025 Q4	$356K	Sell	29,487 -34,409	-54%	-$467K	﹤0.01%	2902
2025 Q3	$868K	Buy	+63,896	New	+$601K	﹤0.01%	2635
2025 Q2	–	Sell	-24,013	Closed	-$85K	–	3622
2025 Q1	$85K	Buy	+24,013	New	+$85.5K	﹤0.01%	3168
2023 Q4	–	Sell	-267,694	Closed	-$4.9M	–	2310
2023 Q3	$4.9M	Buy	267,694 +46,561	+21%	+$985K	0.06%	442
2023 Q2	$4.77M	Sell	221,133 -465	-0.2%	-$12.6K	0.06%	380
2023 Q1	$6.5M	Sell	221,598 -38,953	-15%	-$1.35M	0.09%	292
2022 Q4	$9.63M	Sell	260,551 -51,865	-17%	-$1.84M	0.15%	163
2022 Q3	$8.79M	Sell	312,416 -637,713	-67%	-$15.9M	0.1%	245
2022 Q2	$18.3M	Buy	950,129 +24,776	+3%	+$294K	0.36%	26
2022 Q1	$11.9M	Buy	+925,353	New	+$20.9M	0.14%	121

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Verition Fund Management's AMLX Position: Q1 2026 in Review

Verition Fund Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 55% in Q1 2026, selling an estimated $228K and leaving 13,264 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Verition Fund Management first reported a position in AMLX in Q1 2022 and has held it in 11 quarters since. The position peaked at $18.3M in Q2 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

Verition Fund Management held 13,264 shares of Amylyx Pharmaceuticals worth $184K as of Q1 2026.
Verition Fund Management sold 16,223 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $228K.
Amylyx Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1964 holding.
Verition Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
Verition Fund Management's Amylyx Pharmaceuticals position peaked at $18.3M in Q2 2022.
171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.